Pharmacy Department, Guy's and St Thomas' NHS Foundation Trust, Evelina London Children's Hospital, London, UK.
Institute of Pharmaceutical Science, King's College London, London, UK.
Br J Clin Pharmacol. 2021 Mar;87(3):1338-1346. doi: 10.1111/bcp.14521. Epub 2020 Aug 31.
To evaluate the type (licensed vs unlicensed) and cost of preparations used to fulfil vitamin D prescriptions in England over time, and to compare measured vitamin D content of selected vitamin D preparations against labelled claim.
Retrospective analysis of vitamin D prescription data in primary care in England (2008-2018). Laboratory analysis of 13 selected vitamin D preparations.
Alongside a rise in the number of oral licensed colecalciferol preparations from 0 to 27 between 2012 and 2018, the proportion of vitamin D prescriptions in which licensed vitamin D preparations were supplied increased from 11.8 to 54.2%. However, the use of unlicensed food supplements (dose strength 400-50 000 IU) remained high, accounting for 39.7% of vitamin D prescriptions in 2018. The two licensed preparations showed mean (±SD) vitamin D content of 90.9 ± 0.7% and 90.5 ± 3.9% of the labelled claimed amount, meeting the British Pharmacopeia specification for licensed medicines (90-125% of labelled claim). The 11 food supplements showed vitamin D content ranging from 41.2 ± 10.6% to 165.3 ± 17.8% of the labelled claim, with eight of the preparations failing to comply with the food supplement specification (80-150% of labelled claim).
Despite the increasing availability of quality assured licensed preparations, food supplements continued to be used interchangeably with licensed preparations to fulfil vitamin D prescriptions. Food supplements, manufactured under less stringent quality standards, showed wide variations between measured and declared vitamin D content, which could lead to the risk of under- and over-dosing.
评估在英格兰,随着时间的推移,用于满足维生素 D 处方的制剂类型(许可和非许可)和成本,并比较选定的维生素 D 制剂的实测维生素 D 含量与标签声称。
对英格兰初级保健中维生素 D 处方数据(2008-2018 年)进行回顾性分析。对 13 种选定的维生素 D 制剂进行实验室分析。
2012 年至 2018 年间,口服许可的胆钙化醇制剂数量从 0 增加到 27,与此同时,许可的维生素 D 制剂供应的维生素 D 处方比例从 11.8%增加到 54.2%。然而,未许可的食品补充剂(剂量强度 400-50000 IU)的使用仍然很高,占 2018 年维生素 D 处方的 39.7%。两种许可制剂的实测维生素 D 含量分别为标签声称量的 90.9±0.7%和 90.5±3.9%,符合英国药典对许可药物的规格(90-125%的标签声称)。11 种食品补充剂的实测维生素 D 含量范围为标签声称量的 41.2±10.6%至 165.3±17.8%,其中 8 种制剂不符合食品补充剂规格(80-150%的标签声称)。
尽管质量保证的许可制剂的供应不断增加,但食品补充剂仍与许可制剂交替使用以满足维生素 D 处方。在较低的质量标准下生产的食品补充剂,实测和声明的维生素 D 含量之间存在很大差异,这可能导致剂量不足和过量的风险。